RUNX1T1

Primary Author(s)*

Brian Davis, PhD

Synonyms

"RUNX1 translocation partner 1"; "Cyclin-D-Related Protein"; CDR; "Eight Twenty One Protein"; ETO; "Myeloid Translocation Gene On 8q22"; MTG8; "Acute Myelogenous Leukemia 1 Translocation 1"; AML1T1; "Zinc Finger MYND Domain-Containing Protein 2"; ZMYND2; "Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated To, 1; Cyclin D-Related"; CBFA2T1; AML1-MTG8

Genomic Location

Cytoband: 8q21.3

Genomic Coordinates:

chr8:91,954,967-92,103,286(GRCh38/hg38)

chr8:92,967,195-93,115,514(GRCh37/hg19)

Cancer Category/Type

Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1

The t(8;21)(q22;q22) (RUNXT1, RUNX1) translocation is one of the most frequent karyotypic abnormalities in acute myeloid leukemia with a reported incidence of 7% [5,7]. The translocation t(8;21)(q22;q22.1);_RUNX1-RUNX1T1 produces a chimeric gene made up of the 5'-region of the runt-related transcription factor 1 (RUNX1) gene fused to the 3'-region of the RUNX1T1 gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.

Gene Overview

The RUNX1T1 gene is a member of the human myeloid translocation genes (MTGs). The nuclear MTGs can mediate the formation of complex protein networks among nuclear corepressors (for example Sin3a, N-CoR, SMRT), chromatin-modifying enzymes (for example histone deacetylases), and DNA-binding transcription factors. Repression at target genes by MTG protein complexes is probably required for gene regulation during development and differentiation. Alterations in these genes can disrupt gene regulatory protein networks and can cause of cancers and neurodegeneration [8] The translocation t(8;21)(q22;q22.1);_RUNX1-RUNX1T1 produces a chimeric gene made up of the 5'-region of the runt-related transcription factor 1 (RUNX1) gene fused to the 3'-region of the RUNX1T1 gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.

Common Alteration Types

Acute Myeloid Leukemia (AML)

The t(8;21)(q22;q22) (RUNXT1, RUNX1) translocation is one of the most frequent karyotypic abnormalities in acute myeloid leukemia with a reported incidence of 7% [5,7].

Copy Number Loss	Copy Number Gain	LOH	Loss-of-Function Mutation	Gain-of-Function Mutation	Translocation/Fusion
					X

Internal Pages

Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms

Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1

External Links

RUNX1T1 by Atlas of Genetics and Cytogenetics in Oncology and Haematology - detailed gene information

RUNX1T1 by COSMIC - sequence information, expression, catalogue of mutations

RUNX1T1 by St. Jude ProteinPaint mutational landscape and matched expression data.

RUNX1T1 by Precision Medicine Knowledgebase (Weill Cornell) - manually vetted interpretations of variants and CNVs

RUNX1T1 by My Cancer Genome - brief gene overview

RUNX1T1 by UniProt - protein and molecular structure and function

RUNX1T1 by Pfam - gene and protein structure and function information

RUNX1T1 by GeneCards - general gene information and summaries

RUNX1T1 by NCBI Gene - general gene information and summaries

References

1. Trippier, P. C. (2017). Small molecule inhibitors for acute myeloid leukemia: where is the field heading? Future Med. Chem. 13:1453-1456. PMID 28795593 doi: 10.4155/fmc-2017-0114

2. Bellissimo, D.C. and Speck, N. A. (2017). RUNX1 Mutations in Inherited and Sporadic Leukemia. Front Cell Dev. Biol. 5: 111 PMID 29326930 10.3389/fcell.2017.00111

3. Wang, et al. (2017). Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia. Stem Cells Int. 2017:6962379 PMID 28197208 doi: 10.1155/2017/6962379

4. Kamikubo, Y. (2018). Genetic compensation of RUNX family transcription factors in leukemia. Cancer Sci. (online version ahead of publication). PMID 29883054 doi.org/10.1111/cas.13664.

5. Post SM. et al. (2015). Biology of Adult Myelocytic Leukemia and Myeldysplasia in The Molecular Basis of Cancer, 4th edition. Mendelsohn, J, Howley, PM, Israel, MA, Gray, JW, Thompson, CB. Editors. Elsevier Press: Philadelphia, USA, p395-406.

6. Taylor, J. et al. (2017). Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 130:410-423. PMID 28600336 doi: 10.1182/blood-2017-02-734541.

7. Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. Revised 4th Edition. IARC Press: Lyon, France, p140-141.

8. Rossetti S. et al. (2004). The MTG proteins: chromatin repression players with a passion for networking. Genomics 84:1-9. PMID: 15203199 DOI 10.1016/j.ygeno.2004.02.011

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.